Results 201 to 210 of about 4,730,453 (227)

Siponimod for relapsing-remitting multiple sclerosis: a single-center, real-world cohort study in China. [PDF]

BMC Neurol
Tan H, Zhou L, Gao Y, Zhao C, Lu C, Dong Q, ZhangBao J, Quan C.   +7 more
europepmc   +1 more source

A potential of serum anti-C1P IgG antibodies as biomarkers in differential diagnosis of relapsing-remitting multiple sclerosis. [PDF]

Sci Rep
Chojdak-Lukasiewicz J, Jakubiak-Augustyn A, Szulc ZM, Gubernator J, Blazej P, Pokryszko-Dragan A, Budrewicz S, Podbielska M.   +7 more
europepmc   +1 more source

Twenty-Four-Month Real-World Outcomes of Ofatumumab in Relapsing-Remitting Multiple Sclerosis: A Multicenter Retrospective Cohort Study. [PDF]

J Clin Med
Galus W, Kiełbowicz-Hołysz M, Siuda J, Gajewska G, Lasek-Bal A, Puz P.   +5 more
europepmc   +1 more source

A Stage-Dependent Translational Signature in Peripheral Blood Mononuclear Cells from Clinically Isolated Syndrome to Relapsing-Remitting Multiple Sclerosis: An Exploratory Cross-Sectional Study. [PDF]

Int J Mol Sci
D'Angiolini S, Minuti A.
europepmc   +1 more source

Functional Training Mitigates Reduced Circulating Indole-3-Lactate Levels in Persons With Relapsing-Remitting Multiple Sclerosis. [PDF]

Acta Physiol (Oxf)
Wences Chirino T, Adammek F, Belen S, Winker M, Proschinger S, Rademacher A, Schlagheck ML, Schenk A, Kupjetz M, Walzik D, Warnke C, Reuter M, Rosenberger F, Meyer T, McCann A, Ueland PM, Joisten N, Zimmer P.   +17 more
europepmc   +1 more source

Effectiveness and Safety of Cladribine in Relapsing-Remitting Multiple Sclerosis in Clinical Practice: A 2-Year Multicenter Retrospective Open-Label Study. [PDF]

Ann Indian Acad Neurol
Fortes-González MS, Herrero-Poch L, Pato-Pato A, Soto JG, Multiple Sclerosis Study Group of the Galician Society of Neurology.   +4 more
europepmc   +1 more source

Personalizing Relapsing-Remitting Multiple Sclerosis Monitoring: Patient Acceptance of Serum Neurofilament Light Chain and the Role of Disease Knowledge. [PDF]

J Pers Med
Pérez-Sempere Á, García-Arcelay E, Pérez JC, Candeliere-Merlicco A, Orviz A, Martín-Martínez J, Piñar-Morales R, Álvarez-Rodríguez E, Pacheco-Cortegana EM, Borrega L, Casanova I, Caminero AB, Sánchez-Menoyo JL, Gómez-Gutiérrez M, Carmona O, Calles C, Hernández MÁ, López-Muñoz P, Bakdache F, Monreal E, González-Suárez I, Maurino J.   +21 more
europepmc   +1 more source

Risk factors for relapse in relapsing remitting multiple sclerosis [PDF]

British Journal of Neuroscience Nursing, 2021
Relapsing remitting is the most common type of multiple sclerosis, affecting approximately 85% of all patients. Previous evidence has suggested that the risk factors for developing relapsing remitting multiple sclerosis is multifactorial.
James Hill, Karen Palmer
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Elevated sCD40L in Secondary Progressive Multiple Sclerosis in Comparison to Non-progressive Benign and Relapsing Remitting Multiple Sclerosis

Journal of Central Nervous System Disease, 2021
Yang Mao-Draayer, Jennifer Yang, Qin Wang   +2 more
exaly  

Quantitative magnetization transfer imaging in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.

Brain Communications, 2022
Michael Jonathan Thrippleton, Elizabeth York, Rozanna Meijboom   +2 more
exaly